Form 4 holding
Director
Arcus Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 44,300
- Estimated value
- $956,880
- Report date
- 11 Jun 2026
- Price
- $21.60
- Ownership
- Direct
Patrick Machado
Insider Reports History
- Reporting-owner location
- San Francisco, CA
- Latest reporting-owner signature
-
/s/ Sanam Pangali, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Patrick Machado
Form 4 holding
Director
ALUMIS INC.
- Security class
- Common Stock
- Shares / value
- 7,064
- Estimated value
- $155,619
- Report date
- 30 Jun 2026
- Price
- $22.03
- Ownership
- By Trust
Form 4 holding
Director
Xenon Pharmaceuticals Inc.
- Security class
- Common Shares
- Shares / value
- 2,645
- Estimated value
- $153,806
- Report date
- 01 Jun 2026
- Price
- $58.15
- Ownership
- Direct
Form 4 holding
Director
ALUMIS INC.
- Security class
- Common Stock
- Shares / value
- 3,553
- Estimated value
- $78,272
- Report date
- 30 Jun 2026
- Price
- $22.03
- Ownership
- Direct
Form 4 holding
Director
ACELYRIN, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 21 May 2025
- Price
- $2.45
- Ownership
- Indirect
Form 4 holding
Director
Adverum Biotechnologies, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 09 Dec 2025
- Price
- $4.26
- Ownership
- Direct
Form 4 holding
Director
CHIMERIX INC
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 60,000
- Estimated value
- Report date
- 09 Jun 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Arcus Biosciences, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 16,900
- Estimated value
- Report date
- 11 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Stock Option (Rights to Buy)
- Underlying amount
Form 4 holding
Director
ALUMIS INC.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 15,528
- Estimated value
- Report date
- 30 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Xenon Pharmaceuticals Inc.
- Security class
- Share Option (Right to Buy)
- Shares / value
- 10,507
- Estimated value
- Report date
- 03 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
Form 4 holding
Director
Xenon Pharmaceuticals Inc.
- Security class
- Restricted Share Units
- Shares / value
- 1,593
- Estimated value
- Report date
- 03 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
Form 4 holding
Director
ACELYRIN, Inc.
- Security class
- Director Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 21 May 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Adverum Biotechnologies, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 09 Dec 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Turning Point Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 17 Aug 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Patrick Machado
4
ALMS
ALUMIS INC.
- Report period
- 30 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2026, 18:24
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 11 Jun 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2026, 16:28
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 01 Jun 2026
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2026, 21:04
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 09 Dec 2025
- Transactions
- 13
- Transaction value
- $0
- Accepted by SEC
- 10 Dec 2025, 13:22
- Role
- Director
- Next action
- Open filing details
4
ALMS
ALUMIS INC.
- Report period
- 30 Jul 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Aug 2025, 16:05
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 17 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2025, 16:21
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 10 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2025, 16:28
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 05 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 18:00
- Role
- Director
- Next action
- Open filing details
4
SLRN
ACELYRIN, Inc.
- Report period
- 21 May 2025
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 23 May 2025, 16:06
- Role
- Director
- Next action
- Open filing details
4
ALMS
ALUMIS INC.
- Report period
- 21 May 2025
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 23 May 2025, 16:05
- Role
- Director
- Next action
- Open filing details
4
ALMS
ALUMIS INC.
- Report period
- 27 Jun 2024
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 01 Jul 2024, 16:41
- Role
- Director
- Next action
- Open filing details
3
ALMS
ALUMIS INC.
- Report period
- 27 Jun 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 16:09
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 17 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2024, 16:43
- Role
- Director
- Next action
- Open filing details
4
SLRN
ACELYRIN, Inc.
- Report period
- 07 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Jun 2024, 19:09
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 06 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 18:20
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 05 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2024, 17:42
- Role
- Director
- Next action
- Open filing details
4
SLRN
ACELYRIN, Inc.
- Report period
- 04 Oct 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Oct 2023, 17:56
- Role
- Director
- Next action
- Open filing details
3
TSBX
Turnstone Biologics Corp.
- Report period
- 20 Jul 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 20 Jul 2023, 21:52
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2023, 20:05
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 09 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2023, 17:02
- Role
- Director
- Next action
- Open filing details
4
CHIMERIX INC
- Report period
- 09 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 16:28
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 02 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2023, 17:20
- Role
- Director
- Next action
- Open filing details
4
SLRN
ACELYRIN, Inc.
- Report period
- 09 May 2023
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 11 May 2023, 21:09
- Role
- Director
- Next action
- Open filing details
4
SLRN
ACELYRIN, Inc.
- Report period
- 04 May 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 May 2023, 20:16
- Role
- Director
- Next action
- Open filing details
3
SLRN
ACELYRIN, Inc.
- Report period
- 04 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 04 May 2023, 19:47
- Role
- Director
- Next action
- Open filing details
4
Turning Point Therapeutics, Inc.
- Report period
- 17 Aug 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 17 Aug 2022, 16:41
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 28 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 29 Jun 2022, 17:34
- Role
- Director
- Next action
- Open filing details
4
CHIMERIX INC
- Report period
- 23 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2022, 11:10
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 14 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2022, 16:26
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2022, 16:19
- Role
- Director
- Next action
- Open filing details
3
ROIV
Roivant Sciences Ltd.
- Report period
- 01 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Oct 2021, 17:43
- Role
- Director
- Next action
- Open filing details
4
CHIMERIX INC
- Report period
- 23 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 25 Jun 2021, 17:24
- Role
- Director
- Next action
- Open filing details
4
RCUS
Arcus Biosciences, Inc.
- Report period
- 03 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2021, 16:40
- Role
- Director
- Next action
- Open filing details
4
XENE
Xenon Pharmaceuticals Inc.
- Report period
- 03 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2021, 21:09
- Role
- Director
- Next action
- Open filing details
4
Turning Point Therapeutics, Inc.
- Report period
- 02 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2021, 17:41
- Role
- Director
- Next action
- Open filing details
4
ADVM
Adverum Biotechnologies, Inc.
- Report period
- 12 May 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 May 2021, 20:01
- Role
- Director
- Next action
- Open filing details